Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia.
作者信息
Cruz Martin P
出版信息
P T. 2011 Aug;36(8):489-92.
Abstract
摘要
相似文献
1
2
Lurasidone (latuda®): an atypical antipsychotic.鲁拉西酮（利培酮）：一种非典型抗精神病药物。
Issues Ment Health Nurs. 2012 May;33(5):342-3. doi: 10.3109/01612840.2012.669025.
4
The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.新型抗精神病药物鲁拉西酮增强 N-甲基-D-天冬氨酸受体介导的突触反应。
Mol Pharmacol. 2012 Feb;81(2):113-9. doi: 10.1124/mol.111.076141. Epub 2011 Nov 9.
5
Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.鲁拉西酮治疗精神分裂症：这一新批准的第二代抗精神病药物的疗效和安全性概况综述。
Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3.
6
Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.精神分裂症患者中鲁拉西酮及其他口服非典型抗精神病药物的真实世界依从性评估：一项行政索赔分析
Curr Med Res Opin. 2017 May;33(5):813-820. doi: 10.1080/03007995.2017.1284656. Epub 2017 Feb 6.
7
Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.比较氨磺必利与其他非典型抗精神病药单药治疗青少年精神分裂症的系统文献评价和网络荟萃分析。
Eur Child Adolesc Psychiatry. 2020 Sep;29(9):1195-1205. doi: 10.1007/s00787-019-01425-2. Epub 2019 Nov 22.
8
Lurasidone: an atypical antipsychotic for schizophrenia.鲁拉西酮：一种用于治疗精神分裂症的非典型抗精神病药。
Ann Pharmacother. 2012 Jul-Aug;46(7-8):1033-46. doi: 10.1345/aph.1M721. Epub 2012 Jul 24.
9
Lurasidone for schizophrenia.用于治疗精神分裂症的鲁拉西酮
Drug Ther Bull. 2015 Mar;53(3):30-2. doi: 10.1136/dtb.2015.3.0313.
10
Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression?鲁拉西酮所致血小板减少症：它是药物性骨髓抑制的信号吗？
Indian J Psychol Med. 2018 Mar-Apr;40(2):191-192. doi: 10.4103/IJPSYM.IJPSYM_374_17.
引用本文的文献
1
Bioequivalence study of two formulations of lurasidone film coated tablets in healthy subjects under fed conditions.两种剂型的鲁拉西酮薄膜包衣片在健康受试者进食条件下的生物等效性研究。
Sci Rep. 2025 Jul 1;15(1):20492. doi: 10.1038/s41598-025-04800-z.
2
Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence.鲁拉西酮在西班牙的用途和剂量：RETROLUR，一项使用人工智能的真实世界回顾性分析。
Front Psychiatry. 2025 Feb 5;15:1506142. doi: 10.3389/fpsyt.2024.1506142. eCollection 2024.
3
Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes.孕期抗精神病药物和心境稳定剂的比较安全性：先天性畸形和产前结局的系统评价与网状荟萃分析
CNS Drugs. 2025 Jan;39(1):1-22. doi: 10.1007/s40263-024-01131-x. Epub 2024 Nov 11.
4
Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy.鲁拉西酮治疗精神分裂症和双相抑郁：疗效综述
Cureus. 2023 Apr 24;15(4):e38071. doi: 10.7759/cureus.38071. eCollection 2023 Apr.
5
Superficial and Inkjet Scalable Printed Sensors Integrated with Iron Oxide and Reduced Graphene Oxide for Sensitive Voltammetric Determination of Lurasidone.集成氧化铁和还原氧化石墨烯的用于伏安法灵敏测定卢拉西酮的表面和喷墨可扩展印刷传感器
ACS Omega. 2023 Mar 9;8(11):10449-10458. doi: 10.1021/acsomega.3c00040. eCollection 2023 Mar 21.
6
Improving Lurasidone Hydrochloride's Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin.通过与羟丙基-β-环糊精形成高阶配合物提高盐酸鲁拉西酮的溶解度和稳定性
Pharmaceutics. 2023 Jan 10;15(1):232. doi: 10.3390/pharmaceutics15010232.
7
Olfactory Reference Syndrome Treated With Lurasidone and Cognitive Behavioral Therapy: A Case Report.用鲁拉西酮和认知行为疗法治疗嗅觉参考综合征：一例报告
Clin Med Insights Case Rep. 2022 Nov 28;15:11795476221139396. doi: 10.1177/11795476221139396. eCollection 2022.
8
A study of the structure-affinity relationship in SYA16263; is a D receptor interaction essential for inhibition of apormorphine-induced climbing behavior in mice?SYA16263 构效关系研究：D 受体相互作用是否对抑制阿扑吗啡诱导的小鼠攀爬行为至关重要？
Bioorg Med Chem. 2021 Jan 15;30:115943. doi: 10.1016/j.bmc.2020.115943. Epub 2020 Dec 14.
9
Use of Antipsychotic Drugs During Pregnancy.孕期使用抗精神病药物。
Curr Treat Options Psychiatry. 2019 Mar;6(1):17-31. doi: 10.1007/s40501-019-0165-5. Epub 2019 Jan 30.
10
Lurasidone-induced anemia: Is there a need for hematological monitoring?鲁拉西酮致贫血：是否需要进行血液学监测？
Indian J Pharmacol. 2019 Jul-Aug;51(4):276-278. doi: 10.4103/ijp.IJP_434_18.
本文引用的文献
1
The economic burden of schizophrenia in the United States in 2002.2002年美国精神分裂症的经济负担。
J Clin Psychiatry. 2005 Sep;66(9):1122-9. doi: 10.4088/jcp.v66n0906.
2
Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review.精神分裂症中通过面部表情和情感韵律进行情绪识别：方法学综述
Clin Psychol Rev. 2002 Jul;22(6):789-832. doi: 10.1016/s0272-7358(02)00130-7.
3
Atypical antipsychotics: mechanism of action.非典型抗精神病药物：作用机制
Can J Psychiatry. 2002 Feb;47(1):27-38.
4
Dimensional approach to delusions: comparison across types and diagnoses.妄想的维度研究方法：不同类型与诊断之间的比较
Am J Psychiatry. 1999 Dec;156(12):1938-43. doi: 10.1176/ajp.156.12.1938.
5
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.精神分裂症的精神病症状：患病率、对非典型抗精神病药物的反应及预后预测
Biol Psychiatry. 1999 Aug 1;46(3):361-4. doi: 10.1016/s0006-3223(99)00040-2.
6
Outcome in schizophrenia: beyond symptom reduction.精神分裂症的预后：超越症状缓解
J Clin Psychiatry. 1999;60 Suppl 3:3-7; discussion 8.
7
Dimensions of schizophrenic positive symptoms: an exploratory factor analysis investigation.精神分裂症阳性症状的维度：一项探索性因素分析研究。
Eur Arch Psychiatry Clin Neurosci. 1998;248(3):130-5. doi: 10.1007/s004060050029.
8
Five-factor model of schizophrenia. Initial validation.
J Nerv Ment Dis. 1994 Nov;182(11):631-8. doi: 10.1097/00005053-199411000-00006.
9
Negative symptoms in schizophrenia. Definition and reliability.精神分裂症的阴性症状。定义及可靠性。
Arch Gen Psychiatry. 1982 Jul;39(7):784-8. doi: 10.1001/archpsyc.1982.04290070020005.
10
Neuropsychological function in schizophrenia. Selective impairment in memory and learning.精神分裂症中的神经心理功能。记忆和学习方面的选择性损害。
Arch Gen Psychiatry. 1991 Jul;48(7):618-24. doi: 10.1001/archpsyc.1991.01810310036007.
Zotero 插件